Hemolytic-uremic syndrome historical perspective: Difference between revisions
Jump to navigation
Jump to search
| Line 34: | Line 34: | ||
*The association between [[Shiga toxin|Shiga-toxin]]-producing bacteria and [[Hemolytic-uremic syndrome|HUS]] was made during 35 years ago<ref name=":0" />. | *The association between [[Shiga toxin|Shiga-toxin]]-producing bacteria and [[Hemolytic-uremic syndrome|HUS]] was made during 35 years ago<ref name=":0" />. | ||
*In 1983, Karmali and colleagueswas the first to discover the association between Escherichia coli and the development of [[HUS]]<ref name=":0" />. | *In 1983, Karmali and colleagueswas the first to discover the association between Escherichia coli and the development of [[HUS]]<ref name=":0" />. | ||
*In [year], membrane cofactor protein (MCP), complement factor H (CFH) and factor I (IF) mutations were | *In [year], [[membrane cofactor protein]] (MCP), complement factor H (CFH) and factor I (IF) mutations were implicated in the pathogenesis of non–Shiga toxin–associated HUS<ref>{{Cite journal | ||
| author = [[Jessica Caprioli]], [[Marina Noris]], [[Simona Brioschi]], [[Gaia Pianetti]], [[Federica Castelletti]], [[Paola Bettinaglio]], [[Caterina Mele]], [[Elena Bresin]], [[Linda Cassis]], [[Sara Gamba]], [[Francesca Porrati]], [[Sara Bucchioni]], [[Giuseppe Monteferrante]], [[Celia J. Fang]], [[M. K. Liszewski]], [[David Kavanagh]], [[John P. Atkinson]] & [[Giuseppe Remuzzi]] | | author = [[Jessica Caprioli]], [[Marina Noris]], [[Simona Brioschi]], [[Gaia Pianetti]], [[Federica Castelletti]], [[Paola Bettinaglio]], [[Caterina Mele]], [[Elena Bresin]], [[Linda Cassis]], [[Sara Gamba]], [[Francesca Porrati]], [[Sara Bucchioni]], [[Giuseppe Monteferrante]], [[Celia J. Fang]], [[M. K. Liszewski]], [[David Kavanagh]], [[John P. Atkinson]] & [[Giuseppe Remuzzi]] | ||
| title = Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome | | title = Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome | ||
| Line 48: | Line 48: | ||
==Outbreaks== | ==Outbreaks== | ||
There have been several outbreaks of | There have been several outbreaks of HUS, which are summarized below: | ||
Shiga toxin-producing (STEC) Escherichia coli O157 | |||
==Landmark Events in the Development of Treatment Strategies== | ==Landmark Events in the Development of Treatment Strategies== | ||
Revision as of 15:35, 20 August 2018
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome historical perspective On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome historical perspective |
|
Hemolytic-uremic syndrome historical perspective in the news |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Historical Perspective
Discovery
- The association between Shiga-toxin-producing bacteria and HUS was made during 35 years ago[2].
- In 1983, Karmali and colleagueswas the first to discover the association between Escherichia coli and the development of HUS[2].
- In [year], membrane cofactor protein (MCP), complement factor H (CFH) and factor I (IF) mutations were implicated in the pathogenesis of non–Shiga toxin–associated HUS[3]
Outbreaks
There have been several outbreaks of HUS, which are summarized below:
Shiga toxin-producing (STEC) Escherichia coli O157
Landmark Events in the Development of Treatment Strategies
In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].
Impact on Cultural History
Famous Cases
The following are a few famous cases of disease name:
References
- ↑ A. Schieppati, P. Ruggenenti, R. P. Cornejo, F. Ferrario, G. Gregorini, P. Zucchelli, E. Rossi & G. Remuzzi (1992). "Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome". Journal of the American Society of Nephrology : JASN. 2 (11): 1640–1644. PMID 1610985. Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 2.2 Phillip I. Tarr, Carrie A. Gordon & Wayne L. Chandler (2005). "Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome". Lancet (London, England). 365 (9464): 1073–1086. doi:10.1016/S0140-6736(05)71144-2. PMID 15781103. Unknown parameter
|month=ignored (help) - ↑ Jessica Caprioli, Marina Noris, Simona Brioschi, Gaia Pianetti, Federica Castelletti, Paola Bettinaglio, Caterina Mele, Elena Bresin, Linda Cassis, Sara Gamba, Francesca Porrati, Sara Bucchioni, Giuseppe Monteferrante, Celia J. Fang, M. K. Liszewski, David Kavanagh, John P. Atkinson & Giuseppe Remuzzi (2006). "Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome". Blood. 108 (4): 1267–1279. doi:10.1182/blood-2005-10-007252. PMID 16621965. Unknown parameter
|month=ignored (help)